Molecular Insight names new board, refocuses on prostate cancer - Ma...

Molecular Insight names new board, refocuses on prostate cancer
Mass High Tech
By Lori Valigra Molecular Insight Pharmaceuticals Inc., a Cambridge clinical-stage biopharma company that exited Chapter 11 last May as a private company, said today that it has elected a new board of directors to guide its focus on prostate cancer.
Molecular Insight Pharmaceuticals, Inc. Elects a New Board of DirectorsMarketWatch (press release)